Arecor Limited, the privately-owned biotech group, has revealed that early clinical trial data has been published for its ultra-rapid acting insulin product candidate.
Peer-reviewed journal Diabetes Care has published online a manuscript detailing the results of Phase I trials of Arecor’s AT247 candidate, a randomized, double blind, crossover study in men with type-1 diabetes.
In the Phase I clinical study, where first dosing began this week, the company said AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with both NovoRapid and Fiasp insulin products.
AT247 is a novel formulation of insulin that aims to accelerate insulin absorption after injection to enable more effective management of blood glucose levels.
The company believes it has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia.
Dr Eva Svehlikova, first author of the study, said: “Publication of these data in a peer-reviewed journal supports the representation of AT247 as a promising candidate in the pursuit for next generation ultra-rapid acting insulin designed to improve postprandial glycemic control and flexibility of dosing.
“This early evidence suggests that AT247 may also facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.”
Sarah Howell, Arecor’s chief executive, said: “Publication of the first AT247 clinical trial marks an important step in our goal to develop a proprietary portfolio of even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with diabetes. With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape.”
The next step on the accelerated development pathway for AT247 will be to further explore its benefits in the clinical setting in 2021.